作者: V. C. McAlister , E. Haddad , E. Renouf , R. A. Malthaner , M. S. Kjaer
DOI: 10.1111/J.1600-6143.2006.01360.X
关键词: Ciclosporin 、 Medicine 、 Tacrolimus 、 Gastroenterology 、 Calcineurin 、 Antibacterial agent 、 Immunosuppression 、 Transplantation 、 Randomized controlled trial 、 Surgery 、 Liver transplantation 、 Internal medicine
摘要: A systematic review of randomized clinical trials (RCT) was undertaken to evaluate the beneficial and harmful effects immunosuppression with cyclosporin versus tacrolimus for liver transplanted patients. MEDLINE, EMBASE, Cochrane Central Hepato-Biliary Group Controlled Trials Registers were searched. Using fixed random model, relative risk (RR), values <1 favoring tacrolimus, 95% confidence intervals (CI) calculated. Of 717 potentially relevant references, 16 RCTs eligible inclusion. Mortality graft loss at 1 year significantly reduced in tacrolimus-treated recipients (Death: RR 0.85, CI 0.73-0.99; loss: 0.73, 0.61-0.86). Tacrolimus number acute rejection (RR 0.81, 0.75-0.88) steroid-resistant 0.54, 0.47-0.74) first year. Lymphoproliferative disorder or dialysis rates not different but more de novo diabetes 1.38, 1.01-1.86) occurred tacrolimus. More patients stopped than 0.57, 0.49-0.66). Treating 100 instead would avoid nine seven respectively, death five two four additional develop after transplantation.